An emerging
healthcare technology company, Zenosense is the holder of an exclusive global
license agreement for the development and marketing of a device for use in
hospitals to detect the Methicillin-resistant Staphylococcus aureus “Super-Bug”
(MRSA). MRSA is a super bug with tremendous implications for strong adverse
effects in healthcare delivery: according to the Centers for Disease Control
and Prevention (CDC), MRSA is responsible for over 11,000 deaths and 80,000
invasive infections per year in just the United States. Annually, those
infections give rise to around $3.2-4.2 billion in U.S. treatment costs.
Overall, the CDC reports that these statistics do not take into consideration
the numbers of less severe infections that have arisen from MRSA.
MRSA is part of a
classification of infections that are acquired in healthcare settings, which
are known as “healthcare-associated infections” (HAIs). On a global scale, it
is estimated that of every 100 hospitalized patients at any given time, 7 in
developed countries and 10 in developing countries will acquire at least one
HAI. In the United States, the Centers for Disease Control and Prevention, and
the U.S. Department of Health and Human Services estimate that one out of every
20 people develop an HAI. In total, approximately 2 million HAIs are associated
with nearly 100,000 deaths each year and are directly responsible for at least
23,000 deaths per year in the United States by itself.
With these
conditions in place, it is clear that advanced diagnostics tools capable of
rapid and effective detection of sources of contamination will greatly
strengthen healthcare delivery. The CDC has issued a report that estimates such
diagnostic tools could give rise to $25-31.5 billion in medical cost savings.
With MRSA accounting for a significant portion of HAI cases, the market
opportunity for an effective MRSA detection device is tremendous.
Through its partner,
the Sgneia Group, Zenosense is working to develop and market an air sniffing
device that aptly and precisely detects MRSA. “Electronic nose” devices have
been shown to exhibit strong capabilities for detection of other harmful
bacteria; the International Space Station, for one, has an Airsense system,
which is capable of detecting in real time various bacteria or diseases, such
as lung cancer. However, these existing systems are bulky, costly, and hard to
install in healthcare settings like patient rooms or emergency healthcare
facilities. This is where Zenosense and its partner’s coming medical innovation
offers potential as a medical game-changer.
Zenosense’s MRSA
detection device will utilize a single commercial, “off-the-shelf” gas sensor
for sampling the air and continuously monitoring for an airborne Volatile
Organic Compounds (“VOCs”) signature emitted by MRSA. This VOC signature only
appears when MRSA has infected and expressed itself as a disease in a patient,
but not necessarily before a patient shows obvious signs of infection. Early
detection of this deadly infection, in turn, can help healthcare providers in
staging early care interventions and reducing their treatment costs.
While the device
will be revolutionary in its functionality and ease-of-use, Zenosense
anticipates it being a highly cost-effective detection option as well.
Specialized hardware developed by Zenosense’s partner will enable the detection
system to perform MRSA identification aptly with just one sensor. Zenosense
says that competitor devices may require as many as 8 to 32 sensors with
supporting components for the same efficacy. Because it will not be as
manufacturing-intensive, the detection unit could be made available to
healthcare settings for a cost per unit below $100.
As Zenosense gains
further traction in the development, approval, and bring-to-market efforts of
this revolutionary medical device, its initiatives are being steered by
experienced management and development teams with professional and
medical-space savvy across a range of areas. These include: material
engineering, business development, advanced sensor technologies development,
advanced technical systems and software development, effective business
strategy mapping and prioritization, market development of products across a
range of sectors, scientific research, and industrial engineering, among
others.
For more
information, visit: www.zenosense.net
About QualityStocks
QualityStocks is committed to connecting subscribers with companies that have huge potential to succeed in the short and long-term future. We offer several ways for investors to find, evaluate, and learn more about investing in these companies.
QualityStocks is committed to connecting subscribers with companies that have huge potential to succeed in the short and long-term future. We offer several ways for investors to find, evaluate, and learn more about investing in these companies.
Sign up for “The QualityStocks Daily Newsletter” at www.QualityStocks.net
The Quality Stocks Daily Blog http://blog.qualitystocks.net
The Quality Stocks Daily Videos http://videocharts.qualitystocks.net
The Quality Stocks “Ones to Watch” http://gotstocks.qualitystocks.net
Please see disclaimer on the QualityStocks website: http://disclaimer.qualitystocks.net
No comments:
Post a Comment